Patents Assigned to KEZAR LIFE SCIENCES, INC.
  • Triazacyclododecansulfonamide (TCD)-based protein secretion inhibitors
    Patent number: 12600711
    Abstract: Provided herein are triazacyclododecansulfonamide (“TCD”)-based protein secretion inhibitors, such as inhibitors of Sec61, methods for their preparation, related pharmaceutical compositions, and methods for using the same. For example, provided herein are compounds of Formula (I) and pharmaceutically acceptable salts and compositions including the same. The compounds disclosed herein may be used, for example, in the treatment of diseases including inflammation and/or cancer.
    Type: Grant
    Filed: May 11, 2022
    Date of Patent: April 14, 2026
    Assignee: KEZAR LIFE SCIENCES, INC.
    Inventor: Henry Johnson
  • Immunoproteasome inhibitor formulations
    Patent number: 12357638
    Abstract: Provided herein are pharmaceutical formulations comprising KZR-616 or a salt thereof, and a sugar, wherein the formulations are lyophilized, methods of preparing said formulations, methods of treating immune-related diseases, and methods of treating inflammation.
    Type: Grant
    Filed: October 4, 2019
    Date of Patent: July 15, 2025
    Assignee: KEZAR LIFE SCIENCES, INC.
    Inventor: Evan Lewis
  • Process of preparing a peptide epoxyketone immunoproteasome inhibitor, and precursors thereof
    Patent number: 11976053
    Abstract: Disclosed herein are methods for preparing [(2S,3R)—N—[(2S)-3-(cyclopent-1-en-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[(2S)-2-[2-(morpholin-4-yl)acetamido]propanamido]propanamide (compound “G”): and precursors thereof.
    Type: Grant
    Filed: October 13, 2022
    Date of Patent: May 7, 2024
    Assignee: KEZAR LIFE SCIENCES, INC.
    Inventors: Henry Johnson, Sean Dalziel, Dustin McMinn